These results demonstrate that PAQR7, PGRMC1, and nPRs can be used as an HCC specific biomarker, while CCM1/3 and PAQR8 can be used as a biomarker signature to differentiate undifferentiated pleomorphic sarcoma (UPS) and hepatic angiosarcoma (HAS) from other hepatic cancer subtypes. Here, PAQR8 is linked to liver angiosarcoma.